CSCIF — COSCIENS Biopharma Inc.

—
OTC · Materials · Chemicals · CIK 1113423 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-13

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 3,143,000 1,737,000 422,000 -202,000 18,851,000 5,278,000 4,009,000
Mar 2026 1,888,000 793,000 -730,000 10,757,000 18,841,000 5,005,000 3,522,000
Dec 2025 1,766,000 609,000 -2,388,000 -2,183,000 21,431,000 7,307,000 17,589,000
Sep 2025 1,483,000 621,000 -2,007,000 -1,819,000 23,859,000 8,524,000 18,779,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,724,000
Investing CF
$-24,000
Financing CF
$-240,000
CapEx
$-305,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$4.23
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-9,953,000
Inventory
$960,000
Receivables
$2,371,000
ST Investments
—
EBIT TTM
$-4,205,000
Pretax Income TTM
$-4,377,000
Interest Exp TTM
$172,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$8,725,000
EBITDA
$-5,214,000
Free Cash Flow
$-3,287,625
Enterprise Value
$2,154,181
Total Cash
$5,278,000
Total Debt
$1,956,000
Shares Out
996,166
Trailing EPS
$-5.47
Book Value
$13.98
ROE
-52.8%
ROA
-16.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,498,000 -10,365,000 -10,358,000 21,431,000 17,589,000 3,842,000 -8,473,000
Dec 2024 9,587,000 -14,023,000 -15,309,000 35,070,000 21,909,000 13,161,000 -14,568,000
Dec 2023 7,143,000 -4,629,000 -3,485,000 23,745,000 2,710,000 21,035,000 -2,582,000
Dec 2022 14,572,000 4,320,000 3,448,000 27,803,176 4,012,218 23,790,959 5,229,000

Peers — same industry

TickerNameMarket CapLastDaily %
PG PROCTER & GAMBLE Co $398.01B $171.72 —
LIN LINDE PLC $236.48B $515.11 —
UL UNILEVER PLC $140.63B $65.31 —
ECL ECOLAB INC. $84.87B $302.59 —
CL COLGATE PALMOLIVE CO $79.18B $99.61 —

News headlines (Yahoo Finance, 1h cache)

COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
2026-11-13 14:34 · Yahoo
COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
2026-10-19 12:00 · Yahoo
COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
2026-09-16 22:00 · Yahoo
COSCIENS ACQUIRES NUALTIS CORP.
2026-09-10 20:15 · Yahoo
COSCIENS Biopharma Inc. Reports Q2 2026 Results
2026-08-11 21:30 · Yahoo
COSCIENS Biopharma Inc. Completes Share Capital Amendment
2026-07-03 12:30 · Yahoo
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
2026-06-18 12:30 · Yahoo
COSCIENS Biopharma Inc. Reports Q1 2026 Results
2026-05-12 21:05 · Yahoo
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
2026-04-20 12:00 · Yahoo
COSCIENS Biopharma: Q3 Earnings Snapshot
2026-11-13 15:51 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.